Skip to main content

MoneyWorks4Me

Biogen Pharmachem Industries informs about statement on deviation or variation

03 Nov 2026 Evaluate

Pursuant to SEBI Circular - CIR/CFD/CMD1/162/2019 dated 24th December, 2019 regarding statement on Deviation or variation for proceeds of public issue/Rights Issue/preferential issue, Qualified institutional placement (QIP) etc., read with Regulation 32(1) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Biogen Pharmachem Industries has informed that: The Company does not have any funds remaining unutilised as on 30th September 2026, or as on date, out of the proceeds of public issue/Rights Issue/preferential issue, qualified institutional placement (QIP) etc., if any undertaken by it at any time in the past. In view of the aforesaid, no information is being provided by way of Annexure-A pursuant to the said Regulation / Circular. 

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Redington 335.35
Adani Enterprises 2590.00
Amrapali Industries 34.25
Maxgrow India 178.70
Rashi Peripheral 801.20
View more..